Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Per Karlsson

Showing results (151-160 of 171) with videos related to

Pageof 18
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPETVictor W Pike, Christer Halldin, Kenji Nobuhara, et al.
Neuroimage|April 25, 2008
[11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brainM Edward Pierson, Jan Andersson, Svante Nyberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.
Journal of the National Cancer Institute|October 18, 2024
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysisPer Karlsson, Anthony Fyles, S Laura Chang, et al.
British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE TrialElena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Pageof 18

Showing results (151-160 of 171) with videos related to

Sort By:
Pageof 18
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT4 receptors with SPETVictor W Pike, Christer Halldin, Kenji Nobuhara, et al.
Neuroimage|April 25, 2008
[11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brainM Edward Pierson, Jan Andersson, Svante Nyberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
British Journal of Cancer|April 20, 2016
Adjuvant ovarian function suppression and cognitive function in women with breast cancerKelly-Anne Phillips, Meredith M Regan, Karin Ribi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.
Journal of the National Cancer Institute|October 18, 2024
Validation of a breast cancer assay for radiotherapy omission: an individual participant data meta-analysisPer Karlsson, Anthony Fyles, S Laura Chang, et al.
British Journal of Cancer|January 18, 2020
Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
British Journal of Cancer|April 11, 2019
Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trialKarin Ribi, Weixiu Luo, Marco Colleoni, et al.
The Lancet. Oncology|November 22, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Weixiu Luo, Per Karlsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2020
Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE TrialElena Guerini-Rocco, Kathryn P Gray, Caterina Fumagalli, et al.
Pageof 18